{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:29:14Z","timestamp":1793946554518,"version":"4.8.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jacadv.2026.102617","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T21:59:13Z","timestamp":1771883953000},"page":"102617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative Strategies to Overcome Diuretic Resistance in Heart Failure"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8684-9010","authenticated-orcid":false,"given":"Ivna GCV.","family":"Lima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jairo T.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana C.","family":"Luk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3440-0523","authenticated-orcid":false,"given":"Darshan H.","family":"Brahmbhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas C.","family":"Godoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2824-1215","authenticated-orcid":false,"given":"Filio","family":"Billia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edimar A.","family":"Bocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2026.102617_bib1","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","article-title":"Acetazolamide in acute decompensated heart failure with volume overload","volume":"387","author":"Mullens","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jacadv.2026.102617_bib2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/eurheartj\/ehac689","article-title":"Hydrochlorothiazide added to intravenous loop diuretics in acute decompensated heart failure (CLOROTIC): a randomized, double-blind, placebo-controlled trial","volume":"44","author":"Trull\u00e0s","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.102617_bib3","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1093\/eurheartj\/ehad341","article-title":"Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics","volume":"44","author":"Yeoh","year":"2023","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102617_bib4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jchf.2019.09.012","article-title":"Diuretic strategies for loop diuretic resistance in acute heart failure: the 3T trial","volume":"8","author":"Cox","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"9","key":"10.1016\/j.jacadv.2026.102617_bib5","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/jamacardio.2017.2198","article-title":"Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial","volume":"2","author":"Butler","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102617_bib6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijcard.2013.12.276","article-title":"Efficacy and safety of high-dose versus low-dose furosemide with or without dopamine infusion: the DAD-HF II trial","volume":"172","author":"Triposkiadis","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacadv.2026.102617_bib7","article-title":"Dapagliflozin in acute heart failure (DAPA-RESPONSE-AHF): a randomized, double-blind, placebo-controlled trial","volume":"83","author":"Cox","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.102617_bib8","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure","volume":"364","author":"Felker","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jacadv.2026.102617_bib9","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1161\/CIRCULATIONAHA.120.048739","article-title":"Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in type 2 diabetes and chronic heart failure: the RECEDE-CHF trial","volume":"142","author":"Mordi","year":"2020","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102617_bib10","first-page":"444","article-title":"Comparison of torasemide and furosemide in heart failure patients: the randomized TORNADO trial","volume":"26","author":"Balsam","year":"2019","journal-title":"Cardiol J"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102617_bib11","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacadv.2026.102617_bib12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.122.059038","article-title":"Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF)","volume":"146","author":"Schulze","year":"2022","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jacadv.2026.102617_bib13","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102617_bib14","article-title":"Continuous versus bolus dosing of furosemide for patients hospitalized for heart failure","volume":"106","author":"Allen","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacadv.2026.102617_bib15","article-title":"Diuretic treatment in high-risk acute decompensation of advanced chronic heart failure\u2014bolus intermittent vs continuous infusion of furosemide: a randomized controlled trial","author":"Frea","year":"2019","journal-title":"Clin Res Cardiol"},{"issue":"11","key":"10.1016\/j.jacadv.2026.102617_bib16","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jacc.2016.12.035","article-title":"Short-Term effects of Tolvaptan in patients with acute heart failure and volume overload","volume":"69","author":"Konstam","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102617_bib17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1388-9842(00)00094-5","article-title":"Effects of high-dose furosemide and small-volume hypertonic saline solution infusion compared with high-dose furosemide as a bolus in refractory congestive heart failure","volume":"2","author":"Paterna","year":"2000","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102617_bib18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ehjcvp\/pvaa132","article-title":"Efficacy and safety of early initiation of eplerenone treatment in patients with acute heart failure (EARLIER trial): a multicentre randomized trial","volume":"8","author":"Asakura","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102617_bib19","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/jama.2022.23924","article-title":"Torsemide versus furosemide in patients hospitalized for heart failure (TRANSFORM-HF)","volume":"329","author":"Mentz","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102617_bib20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijcard.2011.11.087","article-title":"Hypertonic saline solution for prevention of renal dysfunction in patients with decompensated heart failure","volume":"167","author":"Issa","year":"2013","journal-title":"Int J Cardiol"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26000347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26000347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:50:18Z","timestamp":1793944218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26000347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2772963X26000347"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102617","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Strategies to Overcome Diuretic Resistance in Heart Failure","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102617","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102617"}}